Therapeutic regimens based on the use of LHRH analogs and somatostatin analogs might supplement, or in some cases replace, conventional procedures for the treatment of hormone-sensitive cancers. Experimental studies showed that agonists of LHRH might be useful for treatment of androgen-dependent prostate cancer and estrogen-dependent breast cancer. Clinical results accumulated during the past few years support this view. On the basis of experimental findings, LHRH agonists could also be considered as adjuncts for therapy of chondrosarcomas, osteosarcomas, and pancreatic cancer, but the principal approach for the treatment of these neoplasms might be based on somatostatin analogs. In turn, somatostatin analogs could serve as adjuncts in treatment of prostate cancer and breast cancer. Long-acting delivery systems for once-a-month administration of microcapsules of D-Trp6 LHRH have been successfully combined with some chemotherapeutic agents such as Cytoxan and Novantrone in the experimental treatment of prostate cancer. Work is in progress on the use of LHRH analogs for the treatment of ovarian cancer and neoplasms of the female genital tract.
|Original language||English (US)|
|Number of pages||10|
|Journal||Seminars in Reproductive Endocrinology|
|State||Published - Jan 1 1987|
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Reproductive Medicine